Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simpler fitness test could empower spondylarthritis patients to monitor their heart health

NCT ID NCT05926453

Diagnosis Sponsor: Diakonhjemmet Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study is testing whether a simpler, less expensive treadmill test can accurately measure cardiorespiratory fitness in people with spondylarthritis, a chronic inflammatory joint disease. The simpler test will be compared against the gold standard, which uses direct gas exchange measurements. If validated, this easier test could be used more widely in hospitals and community settings, helping patients track their fitness and reduce their risk of cardiovascular disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Maximal cardiorespiratory exercise test using the modified Balke protocol on a treadmill
What this could lead to
If the simpler test proves accurate, it could make fitness testing more accessible for people with spondylarthritis, helping them manage their condition and reduce cardiovascular risk.
What could go wrong
The trial is small and early, and the simpler test may not match the accuracy of the gold standard in this specific patient group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

55 people

The number who actually took part.

Started

Oct 2023

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with spondylarthritis diagnosed by a rheumatologist

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients 18-70 years old with axial SpA according to ASAS criteria Exclusion Criteria: * The American College of Sports Medicine (ACSM) have listed the following contradictions to CPET and participants with absolute or relative contradictions will be excluded. * Absolute contraindications to max CPET: acute myocardial infarction within 2 days, unstable angina, uncontrolled cardiac arrhythmia with hemodynamic compromise, active endocarditis, symptomatic severe aortic stenosis, decompensated heart failure, acute pulmonary embolism, pulmonary infarction, or deep venous thrombosis, acute myocarditis or pericarditis, suspected or known aneurysm, acute systemic infection accompanied by fever, body aches, or swollen lymph glands. * Relative contraindications to max CPET: Left main coronary stenosis, moderate to severe aortic stenosis, arrhythmia (tachydysrhythmia or bradyarrhythmia), recent stroke or transient ischemic attack, resting hypertension with blood pressure systolic \> 200 mmHg and/or diastolic \> 115 mmHg, uncorrected medical conditions, such as significant anaemia, important electrolyte abnormalities imbalance, and hyperthyroidism, uncontrolled metabolic disease (e.g. diabetes, thyrotoxicosis or myxoedema) and chronic infectious disease (e.g. mononucleosis, hepatitis, AIDS). * For the SpA population we have included the following specific exclusion criteria: Unable to walk for less than 15 minutes without support, pregnancy, active uveitis, under- or overweight (BMI: ≤ 18.5 or \> 40)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spondylarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Spondylarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spondylarthritis

Contacts and locations

Locations

  • Diakonhjemmet hospital

    Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.